Agios Pharmaceuticals reports a Schedule 13G showing D. E. Shaw & Co., L.P. and David E. Shaw hold 3,034,031 shares (5.1%) of Common Stock. The filing states shared voting power of 2,863,931 shares and shared dispositive power over 3,034,031 shares. The filing is signed July 2, 2026.
Positive
None.
Negative
None.
Insights
D. E. Shaw reports a 5.1% passive/beneficial stake in Agios via multiple managed accounts.
The filing lists 3,034,031 shares as beneficially owned across three managed vehicles, with 2,863,931 shares subject to shared voting power. This reflects consolidated reporting of advisor-controlled positions rather than direct ownership by David E. Shaw.
Timing and disposition intent are not asserted here; subsequent filings would show any trading activity or changes in holdings.
The Schedule 13G discloses shared control structures and includes a joint filing agreement and power of attorney.
The text explains the reporting arises from relationships among D. E. Shaw entity structures and management roles, and it attaches an Exhibit: Joint Filing Agreement dated July 2, 2026 and a Power of Attorney dated August 1, 2024. These clauses clarify filing authority and aggregation.
For governance impact, note this is a disclosure of holdings; no governance action or control claim is made in the excerpt.
Key Figures
Shares beneficially owned:3,034,031 sharesShared voting power:2,863,931 sharesPercent of class:5.1%+2 more
5 metrics
Shares beneficially owned3,034,031 sharesAggregate holdings reported by D. E. Shaw & Co., L.P. and David E. Shaw
Shared voting power2,863,931 sharesShared power to vote as reported in the filing
Percent of class5.1%Percent of outstanding common stock represented by 3,034,031 shares
Signature date07/02/2026Date signatures were provided on the Schedule 13G
Constituent accounts1,275,312; 861,729; 896,990 sharesShares held in Valence Portfolios, Oculus Portfolios, and under D. E. Shaw IM management
"Item 1. Name of issuer: Agios Pharmaceuticals, Inc."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Beneficially ownedfinancial
"Item 4. Ownership (a) Amount beneficially owned: D. E. Shaw & Co., L.P.: 3,034,031 shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared dispositive powerfinancial
"shared power to dispose or to direct the disposition of: 3,034,031 shares"
Joint Filing Agreementregulatory
"Exhibit 2: Joint Filing Agreement, by and among the Reporting Persons"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does D. E. Shaw report in Agios (AGIO)?
The filing reports 3,034,031 shares, representing 5.1% of Agios common stock. The stake is reported across three managed vehicles and aggregated for disclosure purposes.
How much voting power does D. E. Shaw have in AGIO?
The filing states shared voting power of 2,863,931 shares. Voting authority is described as shared across related D. E. Shaw entities rather than sole voting control.
Does David E. Shaw personally own the reported shares of AGIO?
The filing says David E. Shaw does not own any shares directly and expressly disclaims beneficial ownership while describing shared voting and dispositive powers through affiliated entities.
What documents accompany the Schedule 13G filing for AGIO?
The excerpt lists an Exhibit 1: Power of Attorney dated August 1, 2024 and Exhibit 2: Joint Filing Agreement dated July 2, 2026, which establish authority to file and joint reporting among the reporting persons.
When was the Schedule 13G for AGIO signed?
The signatures in the excerpt are dated 07/02/2026, with filing executed by Daniel R. Marcus as Chief Compliance Officer and as Attorney-in-Fact for David E. Shaw.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Agios Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, Par Value $0.001 per share
(Title of Class of Securities)
00847X104
(CUSIP Number)
06/25/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
00847X104
1
Names of Reporting Persons
D. E. Shaw & Co., L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,863,931.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,034,031.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,034,031.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
00847X104
1
Names of Reporting Persons
David E. Shaw
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,863,931.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,034,031.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,034,031.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Agios Pharmaceuticals, Inc.
(b)
Address of issuer's principal executive offices:
88 Sidney Street, Cambridge, MA 02139
Item 2.
(a)
Name of person filing:
D. E. Shaw & Co., L.P.
David E. Shaw
(b)
Address or principal business office or, if none, residence:
The business address for each reporting person is:
Two Manhattan West
375 Ninth Avenue, 52nd Floor
New York, NY 10001
(c)
Citizenship:
D. E. Shaw & Co., L.P. is a limited partnership organized under the laws of the state of Delaware.
David E. Shaw is a citizen of the United States of America.
(d)
Title of class of securities:
Common Stock, Par Value $0.001 per share
(e)
CUSIP Number(s):
00847X104
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
D. E. Shaw & Co., L.P.: 3,034,031 shares
This is composed of (i) 1,275,312 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 861,729 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., and (iii) 896,990 shares under the management of D. E. Shaw Investment Management, L.L.C.
David E. Shaw: 3,034,031 shares
This is composed of (i) 1,275,312 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 861,729 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., and (iii) 896,990 shares under the management of D. E. Shaw Investment Management, L.L.C.
David E. Shaw does not own any shares directly. By virtue of David E. Shaw's position as President and sole shareholder of D. E. Shaw & Co., Inc., which is the general partner of D. E. Shaw & Co., L.P., which in turn is the investment adviser of D. E. Shaw Valence Portfolios, L.L.C. and D. E. Shaw Oculus Portfolios, L.L.C. and the managing member of D. E. Shaw Investment Management, L.L.C., and by virtue of David E. Shaw's position as President and sole shareholder of D. E. Shaw & Co. II, Inc., which is the managing member of D. E. Shaw & Co., L.L.C., which in turn is the manager of D. E. Shaw Valence Portfolios, L.L.C. and D. E. Shaw Oculus Portfolios, L.L.C., David E. Shaw may be deemed to have the shared power to vote or direct the vote of 2,863,931 shares and the shared power to dispose or direct the disposition of 3,034,031 shares, the 3,034,031 shares as described above constituting 5.1% of the outstanding shares, and, therefore, David E. Shaw may be deemed to be the beneficial owner of such shares. David E. Shaw disclaims beneficial ownership of such 3,034,031 shares.
(b)
Percent of class:
D. E. Shaw & Co., L.P.: 5.1%
David E. Shaw: 5.1%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
D. E. Shaw & Co., L.P.: 0 shares
David E. Shaw: 0 shares
(ii) Shared power to vote or to direct the vote:
D. E. Shaw & Co., L.P.: 2,863,931 shares
David E. Shaw: 2,863,931 shares
(iii) Sole power to dispose or to direct the disposition of:
D. E. Shaw & Co., L.P.: 0 shares
David E. Shaw: 0 shares
(iv) Shared power to dispose or to direct the disposition of:
D. E. Shaw & Co., L.P.: 3,034,031 shares
David E. Shaw: 3,034,031 shares
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
D. E. Shaw & Co., L.P.
Signature:
/s/ Daniel R. Marcus
Name/Title:
Daniel R. Marcus / Chief Compliance Officer
Date:
07/02/2026
David E. Shaw
Signature:
/s/ Daniel R. Marcus
Name/Title:
Daniel R. Marcus / Attorney-in-Fact for David E. Shaw
Date:
07/02/2026
Comments accompanying signature: Exhibit 1: Power of Attorney, granted by David E. Shaw relating to D. E. Shaw & Co., Inc., in favor of the signatories hereto, among others, dated August 1, 2024.
Exhibit Information
Exhibit 2: Joint Filing Agreement, by and among the Reporting Persons, dated July 2, 2026.
